The Financial Express16h
AstraZeneca’s Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
The Pharma Letter2d
AstraZeneca's Fasenra set to revolutionize COPD treatment
UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...
A Breath Away From a Cure: How Xenon Gas Could Transform Alzheimer’s Treatment
A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...
pulmonologyadvisor9d
Study Compares Single-Inhaler Triple Therapies for Treatment of COPD
For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.
emjreviews.com11d
New MRI Lung Scan Technique Offers Hope for Patients Receiving Lung Transplant
New MRI lung scanning method could change treatment for compromised lung function in transplant patients. Read on!
News Medical13d
Study finds no clinical advantage of budesonide inhaler over fluticasone in COPD
A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...
Medscape14d
COPD Updates: What's New in Pathophysiology and Management?
With the earlier definition of chronic obstructive pulmonary disease (COPD), patients were essentially defined as having either chronic bronchitis or emphysema, with emphysema classified as a ...
CNN-News1816d
New Virus In China: What Is Human Metapneumovirus Or HMPV? Symptoms, Treatment Explained
Five years after the initial outbreak, another wave of infections is surging in China. Following COVID-19, a new mysterious virus, Human Metapneumovirus (HMPV), is spreading nationwide. This outbreak ...